Regeneron Pharmaceuticals (REGN)
Open: 476.53 High: 483.40 Low: 474.60
Earnings Per Share
Price To Earnings Ratio
Dividend Payment Date
Regeneron Pharmaceuticals trades on the NASDAQ. REGN's market cap is 50.7 Billion.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products including: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer, and bispecific antibodies and antibody cocktails with other collaborators and independently.
Watch these videos to learn how Symbol Surfing can increase your trading and investing knowledge and results.